Momelotinib

Unassigned

New Medicines

Myelofibrosis

Information

New molecular entity
Sierra Oncology
Sierra Oncology

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2)
The UK incidence of MF is 0.5-1.5 per 100,000 people. The median age at diagnosis is 60 years, and more than 90% of patients are diagnosed after age 40 years. However myelofibrosis has been reported in all age groups. Overall median survival is 5 years.
Myelofibrosis
Oral

Evidence based evaluations